{"id":"placebo-for-eptifibatide","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL1174","moleculeType":"Protein","molecularWeight":"831.98"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Placebo is an inert substance used as a control in clinical trials to establish the efficacy of an active drug through comparison. In this context, it serves as the control arm in a Phase 3 trial for Eptifibatide, a glycoprotein IIb/IIIa inhibitor. Any observed therapeutic benefit in the placebo group is attributed to the placebo effect rather than direct pharmacological action.","oneSentence":"A placebo contains no active pharmaceutical ingredient and produces no pharmacological effect.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:27:07.683Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Control arm in Phase 3 clinical trial for Eptifibatide (acute coronary syndrome, percutaneous coronary intervention)"}]},"trialDetails":[{"nctId":"NCT03735979","phase":"PHASE3","title":"Multi-arm Optimization of Stroke Thrombolysis","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2019-10-15","conditions":"Acute Ischemic Stroke","enrollment":514},{"nctId":"NCT00089895","phase":"PHASE3","title":"EARLY ACS: Early Glycoprotein IIb/IIIa Inhibition in Patients With Non-ST-segment Elevation Acute Coronary Syndrome (Study P03684AM2)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2004-11-01","conditions":"Myocardial Ischemia, Acute Coronary Syndrome","enrollment":9406},{"nctId":"NCT01076764","phase":"PHASE3","title":"Effect of Otamixaban Versus Unfractionated Heparin + Eptifibatide in Patients With Unstable Angina/Non ST Elevation Myocardial Infarction Undergoing Early Invasive Strategy","status":"COMPLETED","sponsor":"Sanofi","startDate":"2010-04","conditions":"Acute Coronary Syndrome","enrollment":13220},{"nctId":"NCT00834899","phase":"PHASE1, PHASE2","title":"A Safety Study of Eptifibatide in Patients With Sickle Cell Disease","status":"TERMINATED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2009-01","conditions":"Sickle Cell Disease","enrollment":13},{"nctId":"NCT01454440","phase":"PHASE4","title":"The INtegrilin Plus STenting to Avoid Myocardial Necrosis Trial (INSTANT)","status":"TERMINATED","sponsor":"University of Turin, Italy","startDate":"2007-10","conditions":"Coronary Artery Disease","enrollment":91},{"nctId":"NCT00638976","phase":"PHASE3","title":"INSTANT: INtegrilin Plus STenting to Avoid Myocardial Necrosis Trial","status":"COMPLETED","sponsor":"Fondazione Evidence per Attività e Ricerche Cardiovascolari ONLUS","startDate":"2007-11","conditions":"Cardiovascular Disease","enrollment":91}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":130,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo (for Eptifibatide)","genericName":"Placebo (for Eptifibatide)","companyName":"Sanofi","companyId":"sanofi","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Eptifibatide is a protein modality drug that inhibits the Integrin alpha-IIb/beta-3, classified as an INHIBITOR. It has been studied in clinical trials for conditions such as coronary artery disease, myocardial ischemia, and acute coronary syndrome, with a randomized trial comparing its efficacy to a placebo in patients undergoing drug-eluting stenting.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}